Director Michael J. Yang of Pacira BioSciences, Inc. filed a Form 4 on November 17, 2026, reporting the disposal of all directly held common stock, restricted stock units, and stock options in connection with the consummation of a cash merger with Viatris Inc.

Key Highlights

  • Merger completed November 17, 2026: Peach Purchaser Sub Inc. merged with and into Pacira BioSciences, Inc., with Pacira continuing as a wholly owned subsidiary of Viatris Inc.
  • Offer Price of $36.50 per share: Each share of common stock was converted into the right to receive $36.50, net of applicable withholding taxes and without interest, according to the filing.
  • 13,393 shares disposed under transaction code U: Yang disposed of 13,393 shares of common stock at $36.50 per share, leaving 6,405 shares beneficially owned directly.
  • Remaining 6,405 shares disposed under transaction code D: Those shares were subsequently disposed of at $36.50 per share, reducing Yang's direct beneficial ownership to zero.
  • Four stock options canceled at the Effective Time: Options to purchase 12,179, 11,279, 10,891, and 30,967 shares of common stock, with exercise prices of $28.68, $24.34, $23.42, and $29.80, respectively, were each canceled and converted into the right to receive cash, per the filing.
  • RSUs also canceled at the Effective Time: Outstanding restricted stock unit awards, whether vested or unvested, were canceled and converted into the right to receive a cash amount per the terms of the Merger Agreement.

Pacira BioSciences Director Reports Zero Beneficial Ownership Following Viatris Acquisition

According to the Form 4 filed on November 17, 2026, Michael J. Yang, a director of Pacira BioSciences, Inc. (NASDAQ:PCRX), reported the complete disposition of his directly held common stock in connection with the closing of a merger under an Agreement and Plan of Merger dated October 8, 2026. The merger involved Pacira BioSciences, Viatris Inc., and Peach Purchaser Sub Inc. The filing states that Purchaser consummated a cash tender offer to purchase all outstanding shares of Pacira's common stock at $36.50 per share, net of applicable withholding taxes and without interest, after which Purchaser merged into Pacira with Pacira surviving as a wholly owned subsidiary of Viatris.

The filing reports two common stock transactions, both dated November 17, 2026. First, 13,393 shares were disposed of at $36.50 per share under transaction code U, reducing Yang's direct holdings to 6,405 shares. Those remaining 6,405 shares were then disposed of at $36.50 per share under transaction code D, leaving Yang with zero directly held shares. The filing attributes both disposals to the terms of the Merger Agreement, under which each share was converted into the right to receive the Offer Price at the Effective Time.

In Table II, the filing reports the cancellation of four stock options held directly by Yang. The options covered 12,179 shares at an exercise price of $28.68 (expiring June 12, 2034), 11,279 shares at $24.34 (expiring June 11, 2035), 10,891 shares at $23.42 (expiring June 10, 2036), and 30,967 shares at $29.80 (expiring October 6, 2033). The filing states that at the Effective Time, each option was canceled and converted into the right to receive cash equal to the product of the number of shares subject to the option multiplied by the excess, if any, of the Offer Price over the per-share exercise price. Options with an exercise price greater than or equal to the Offer Price were canceled with no consideration payable, according to the filing.

What Was Disclosed

The filing disclosed that director Michael J. Yang disposed of all directly held Pacira BioSciences common stock and had all stock options canceled on November 17, 2026, at the Effective Time of the merger with Viatris Inc., resulting in zero remaining beneficial ownership in any security of the issuer.